Blog: Research

MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity

26 February 2020

Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.

Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports

26 February 2020

Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.

Sanofi MS drug results set stage for extensive late-stage testing

12 February 2020

Source Biopharmadive.com: With positive results from a mid-stage study in hand, Sanofi is pushing an experimental multiple sclerosis drug into an extensive late-stage research program comprised of four studies scheduled to begin in the middle of this year.

Gene Variants Linked to High Childhood BMI Point to Higher MS Risk, Study Finds

12 February 2020

Source Multiple Sclerosis News Today: Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS) regardless of a person’s vitamin D levels, a study found.

Multiple Sclerosis Drugs Might Not Need To Reach the Brain To Have Clinical Efficacy

12 February 2020

Source Technology Networks: Scientists from Trinity College Dublin have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS) and other autoimmune diseases such as psoriasis and rheumatoid arthritis.

Siponimod licensed for secondary progressive MS

24 January 2020

Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART)

24 January 2020

Source The Lancet: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource.

Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis

21 January 2020

Source Multiple Sclerosis News Today: Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports.

Brain Regeneration Impaired in Progressive MS, Unaffected By DMTs, Study Reports

21 January 2020

Source Multiple Sclerosis News Today: Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports.

From depression to dementia, inflammation is medicine’s new frontier

21 January 2020

Source The Guardian: The barrier between mind and body appears to be crumbling. Clinical practice and public perception need to catch up.

Unlikely as it may seem, #inflammation has become a hashtag. It seems to be everywhere suddenly, up to all sorts of tricks. Rather than simply being on our side, fighting infections and healing wounds, it turns out to have a dark side as well: the role it plays in causing us harm.

It’s now clear that inflammation is part of the problem in...

Pages

Category

Archive